

Theodoros Dimitroulas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2568962/publications.pdf>

Version: 2024-02-01

156
papers

2,711
citations

201674

27
h-index

254184

43
g-index

158
all docs

158
docs citations

158
times ranked

3600
citing authors

#	ARTICLE	IF	CITATIONS
1	The effects of golimumab on work productivity and quality of life among work-active axial spondyloarthritis and psoriatic arthritis patients treated in the routine care in Greece: the "GO-UP" study. <i>Quality of Life Research</i> , 2022, 31, 1385-1399.	3.1	1
2	Better outcomes of COVID-19 in vaccinated compared to unvaccinated patients with systemic rheumatic diseases. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1013-1016.	0.9	43
3	Arterial stiffness in rheumatoid arthritis: Current knowledge and future perspectives. <i>Indian Journal of Rheumatology</i> , 2022, 17, 157.	0.4	0
4	Humoral and cellular response to a third booster dose SARS-CoV-2 vaccination in patients with autoimmune disease: a case series. <i>Scandinavian Journal of Rheumatology</i> , 2022, 51, 422-424.	1.1	3
5	Methotrexate induced neurotoxicity in a patient with rheumatoid arthritis on rituximab therapy: a case-based review. <i>Rheumatology International</i> , 2022, 42, 1849-1854.	3.0	4
6	Comparable or higher prevalence of comorbidities in antiphospholipid syndrome vs rheumatoid arthritis: a multicenter, case-control study. <i>Rheumatology</i> , 2021, 60, 170-178.	1.9	24
7	Immune checkpoint inhibitor-induced musculoskeletal manifestations. <i>Rheumatology International</i> , 2021, 41, 33-42.	3.0	32
8	Microcirculatory function deteriorates with advancing stages of chronic kidney disease independently of arterial stiffness and atherosclerosis. <i>Hypertension Research</i> , 2021, 44, 179-187.	2.7	17
9	The presence of diabetes mellitus further impairs structural and functional capillary density in patients with chronic kidney disease. <i>Microcirculation</i> , 2021, 28, e12665.	1.8	12
10	Outcome of refractory to conventional and/or biologic treatment adult Still's disease following canakinumab treatment: Countrywide data in 50 patients. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 137-143.	3.4	22
11	Incidence, risk factors and validation of the RABBIT score for serious infections in a cohort of 1557 patients with rheumatoid arthritis. <i>Rheumatology</i> , 2021, 60, 2223-2230.	1.9	8
12	Nailfold videocapillaroscopy: a novel possible surrogate marker for the evaluation of peripheral microangiopathy in pulmonary arterial hypertension. <i>Scandinavian Journal of Rheumatology</i> , 2021, 50, 85-94.	1.1	6
13	Cardiovascular Magnetic Resonance Reveals Cardiac Pathophysiology in Autoimmune Rheumatic Diseases. <i>Mediterranean Journal of Rheumatology</i> , 2021, 31, 15.	0.8	9
14	Identifying unmet needs in SSc-ILD by semi-qualitative in-depth interviews. <i>Rheumatology</i> , 2021, 60, 5601-5609.	1.9	10
15	Ventricular Tachycardia Has Mainly Non-Ischaemic Substrates in Patients with Autoimmune Rheumatic Diseases and a Preserved Ejection Fraction. <i>Diagnostics</i> , 2021, 11, 519.	2.6	1
16	Nailfold Capillaroscopy in Systemic Sclerosis Patients with and without Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 1528.	2.4	17
17	Vascular endothelial injury assessed with functional techniques in systemic sclerosis patients with pulmonary arterial hypertension versus systemic sclerosis patients without pulmonary arterial hypertension: a systematic review and meta-analysis. <i>Rheumatology International</i> , 2021, 41, 1045-1053.	3.0	10
18	Cardiovascular comorbidity in rheumatic and musculoskeletal diseases: Where we are and how can we move forward?. <i>International Journal of Rheumatic Diseases</i> , 2021, 24, 473-476.	1.9	4

#	ARTICLE	IF	CITATIONS
19	P628 Risk Factors Associated with Extraintestinal Manifestations in Patients with Inflammatory Bowel Diseases. <i>Journal of Crohn's and Colitis</i> , 2021, 15, S566-S566.	1.3	0
20	Nailfold videocapillaroscopic changes in patients with pulmonary arterial hypertension associated with connective tissue diseases. <i>Rheumatology International</i> , 2021, 41, 1289-1298.	3.0	5
21	Effect of Biologics on Cardiovascular Inflammation: Mechanistic Insights and Risk Reduction. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 1915-1931.	3.5	21
22	Peripheral microcirculatory abnormalities are associated with cardiovascular risk in systemic sclerosis: a nailfold video capillaroscopy study. <i>Clinical Rheumatology</i> , 2021, 40, 4957-4968.	2.2	12
23	Peripheral microangiopathy in Eisenmenger syndrome: A nailfold video capillaroscopy study. <i>International Journal of Cardiology</i> , 2021, 336, 54-59.	1.7	7
24	Peripheral microangiopathy in precapillary pulmonary hypertension: a nailfold video capillaroscopy prospective study. <i>Respiratory Research</i> , 2021, 22, 27.	3.6	20
25	Association Between Uric Acid and Worsening Peripheral Microangiopathy in Systemic Sclerosis. <i>Frontiers in Medicine</i> , 2021, 8, 806925.	2.6	4
26	Monitoring and Managing Cardiovascular Risk in Immune Mediated Inflammatory Diseases. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 6893-6906.	3.5	8
27	Cardiac magnetic resonance predicts ventricular arrhythmias in scleroderma: the Scleroderma Arrhythmia Clinical Utility Study (SAnCtUS). <i>Rheumatology</i> , 2020, 59, 1938-1948.	1.9	42
28	Treatment patterns and achievement of the treat-to-target goals in a real-life rheumatoid arthritis patient cohort: data from 1317 patients. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020, 12, 1759720X2093713.	2.7	10
29	Adrenocorticotrophic hormone: an effective natural biologic therapy for acute gout?. <i>Rheumatology International</i> , 2020, 40, 1941-1947.	3.0	7
30	Subclinical atherosclerosis in systemic sclerosis and rheumatoid arthritis: a comparative matched-cohort study. <i>Rheumatology International</i> , 2020, 40, 1997-2004.	3.0	8
31	P1012 NAIL CAPILLARY DENSITY DURING POSTOCCLUSIVE REACTIVE HYPEREMIA AND VENOUS CONGESTION IS MORE IMPAIRED IN DIABETIC COMPARED TO NON-DIABETIC CKD PATIENTS. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.7	0
32	Comparison of ambulatory central hemodynamics and arterial stiffness in patients with diabetic and non-diabetic CKD. <i>Journal of Clinical Hypertension</i> , 2020, 22, 2239-2249.	2.0	4
33	Cancer risk in systemic sclerosis: identifying risk and managing high-risk patients. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 1105-1113.	3.0	7
34	The Double-Edged Sword of T1-Mapping in Systemic Sclerosis – A Comparison with Infectious Myocarditis Using Cardiovascular Magnetic Resonance. <i>Diagnostics</i> , 2020, 10, 335.	2.6	9
35	Is There a Brain/Heart Interaction in Rheumatoid Arthritis and Seronegative Spondyloarthropathies? A Combined Brain/Heart Magnetic Resonance Imaging Reveals the Answer. <i>Current Rheumatology Reports</i> , 2020, 22, 39.	4.7	3
36	Treatment modalities and drug survival in a systemic sclerosis real-life patient cohort. <i>Arthritis Research and Therapy</i> , 2020, 22, 56.	3.5	12

#	ARTICLE	IF	CITATIONS
37	Current understanding and future perspectives of brain-heart-kidney axis in psoriatic arthritis. <i>Rheumatology International</i> , 2020, 40, 1361-1368.	3.0	1
38	P0156SHORT-TERM BLOOD PRESSURE VARIABILITY IN DIABETIC AND NON-DIABETIC PATIENTS WITH CKD STAGE 2, 3A, 3B AND 4. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.7	0
39	Cardiovascular Risk in Systemic Sclerosis. <i>Current Treatment Options in Rheumatology</i> , 2020, 6, 282-298.	1.4	0
40	Combined Brain-Heart Magnetic Resonance Imaging in Autoimmune Rheumatic Disease Patients with Cardiac Symptoms: Hypothesis Generating Insights from a Cross-Sectional Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 447.	2.4	10
41	AB1201-INCREASING RATES OF INFLUENZA VACCINATION COVERAGE IN RHEUMATOID ARTHRITIS PATIENTS: DATA FROM A MULTICENTER, LONGITUDINAL COHORT STUDY OF 1,406 PATIENTS. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1892.3-1892.	0.9	1
42	Primary Sjögren's Syndrome and Cardiovascular Disease. <i>Current Vascular Pharmacology</i> , 2020, 18, 447-454.	1.7	28
43	Cardiovascular Disease in the Systemic Vasculitides. <i>Current Vascular Pharmacology</i> , 2020, 18, 463-472.	1.7	6
44	Combined Brain/Heart Magnetic Resonance Imaging in Systemic Lupus Erythematosus. <i>Current Cardiology Reviews</i> , 2020, 16, 178-186.	1.5	6
45	Immune checkpoint inhibitor-induced musculoskeletal manifestations. A multicentre prospective study. <i>Mediterranean Journal of Rheumatology</i> , 2020, 31, 239.	0.8	2
46	Practical Issues in Managing Systemic Inflammatory Disorders During the COVID-19 Pandemic. <i>Mediterranean Journal of Rheumatology</i> , 2020, 31, 253.	0.8	3
47	Peripheral Microangiopathy in Patients with Precapillary Pulmonary Hypertension: Correlation with Cardiac Function and Patients' Functional Capacity. Study Design and Rationale. <i>Mediterranean Journal of Rheumatology</i> , 2020, 31, 369.	0.8	8
48	FRIO493-THE INTERLEUKIN-1B INHIBITOR CANAKINUMAB FOR REFRACTORY STILL'S DISEASE: LONG-TERM EXPERIENCE IN 50 CONSECUTIVE PATIENTS. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 845.1-845.	0.9	0
49	FRIO474-IMMUNE CHECKPOINT INHIBITOR-INDUCED MUSCULOSKELETAL MANIFESTATIONS. A SYSTEMATIC REVIEW. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 834.1-834.	0.9	0
50	Novel biomarkers for early targeted and individualized treatment in Juvenile Idiopathic Arthritis. <i>Mediterranean Journal of Rheumatology</i> , 2020, 31, 230.	0.8	1
51	Fever and temporal headache in a 70-year-old male with presumed large vessels vasculitis. <i>Mediterranean Journal of Rheumatology</i> , 2020, 31, 220.	0.8	2
52	Comorbidity burden in systemic sclerosis: beyond disease-specific complications. <i>Rheumatology International</i> , 2019, 39, 1507-1517.	3.0	19
53	Inflammatory bowel diseases and spondyloarthropathies: From pathogenesis to treatment. <i>World Journal of Gastroenterology</i> , 2019, 25, 2162-2176.	3.3	122
54	Targeting very early systemic sclerosis: a case-based review. <i>Rheumatology International</i> , 2019, 39, 1961-1970.	3.0	15

#	ARTICLE	IF	CITATIONS
55	Can we wean patients with inflammatory arthritis from biological therapies?. <i>Autoimmunity Reviews</i> , 2019, 18, 102399.	5.8	5
56	Symptom-based stratification of patients with primary Sjögren's syndrome: multi-dimensional characterisation of international observational cohorts and reanalyses of randomised clinical trials. <i>Lancet Rheumatology</i> , The, 2019, 1, e85-e94.	3.9	76
57	Cardiovascular magnetic resonance in the diagnosis and management of cardiac and vascular involvement in the systemic vasculitides. <i>Current Opinion in Rheumatology</i> , 2019, 31, 16-24.	4.3	13
58	P175 Diagnosing myocardial inflammation in systemic sclerosis and infective myocarditis: are the lake Louise criteria sufficient?. <i>European Heart Journal Cardiovascular Imaging</i> , 2019, 20, .	1.2	0
59	253 Cardiovascular magnetic resonance pattern of acute cardiac events in systemic sclerosis. <i>European Heart Journal Cardiovascular Imaging</i> , 2019, 20, .	1.2	0
60	Genetic regulation of dimethylarginines and endothelial dysfunction in rheumatoid arthritis. <i>Amino Acids</i> , 2019, 51, 983-990.	2.7	6
61	E071 Lack of association between nailfold capillary microscopic changes and cardiovascular risk in systemic sclerosis patients. <i>Rheumatology</i> , 2019, 58, .	1.9	0
62	Platelets in Systemic Sclerosis: the Missing Link Connecting Vasculopathy, Autoimmunity, and Fibrosis?. <i>Current Rheumatology Reports</i> , 2019, 21, 15.	4.7	26
63	Pathophysiology and imaging of heart failure in women with autoimmune rheumatic diseases. <i>Heart Failure Reviews</i> , 2019, 24, 489-498.	3.9	12
64	AB0678 ANTIPROLIFERATIVE AND VASOACTIVE TREATMENT MODALITIES IN 457 CONSECUTIVE PATIENTS WITH SYSTEMIC SCLEROSIS FROM ACADEMIC CENTERS IN GREECE. , 2019, , .		0
65	OP0015 INCIDENCE, RISK FACTORS AND VALIDATION OF THE RABBIT SCORE FOR SERIOUS INFECTIONS IN A REAL LIFE PROSPECTIVE STUDY OF PATIENTS WITH RHEUMATOID ARTHRITIS: DATA FROM 1.549 PATIENTS. , 2019, , .		0
66	SAT0247 FEMALE SEX AND AGE AT DIAGNOSIS ARE ASSOCIATED WITH A DECREASED POSSIBILITY OF DRUG DISCONTINUATION IN GIANT CELL ARTERITIS: DATA FROM A MULTICENTER PROSPECTIVE COHORT OF 177 PATIENTS. , 2019, , .		0
67	Cardiovascular Magnetic Resonance Identifies High-Risk Systemic Sclerosis Patients with Normal Echocardiograms and Provides Incremental Prognostic Value. <i>Diagnostics</i> , 2019, 9, 220.	2.6	28
68	Arterial stiffness correlates with progressive nailfold capillary microscopic changes in systemic sclerosis: results from a cross-sectional study. <i>Arthritis Research and Therapy</i> , 2019, 21, 253.	3.5	18
69	Biologic Drugs as Analgesics for the Management of Low Back Pain and Sciatica. <i>Pain Medicine</i> , 2019, 20, 1678-1686.	1.9	15
70	Pulmonary Arterial Hypertension in Connective Tissue Disorders: The emerging role of screening and early diagnosis. A position paper for Greek Rheumatologists. <i>Mediterranean Journal of Rheumatology</i> , 2019, 30, 90-93.	0.8	4
71	Mediterranean Journal of Rheumatology December 2019 Highlights. <i>Mediterranean Journal of Rheumatology</i> , 2019, 30, 194.	0.8	0
72	Can cardiovascular magnetic resonance prompt early cardiovascular/rheumatic treatment in autoimmune rheumatic diseases? Current practice and future perspectives. <i>Rheumatology International</i> , 2018, 38, 949-958.	3.0	20

#	ARTICLE	IF	CITATIONS
73	Mixed Methods Study Identifying Key Intervention Targets to Improve Participation in Daily Living Activities in Primary Sjögren's Syndrome Patients. <i>Arthritis Care and Research</i> , 2018, 70, 1064-1073.	3.4	15
74	A case of sarcoidosis-associated pulmonary hypertension masquerading as chronic thromboembolic pulmonary hypertension. <i>Pulmonary Circulation</i> , 2018, 8, 1-6.	1.7	4
75	Pyoderma gangrenosum and pyogenic arthritis presenting as severe sepsis in a rheumatoid arthritis patient treated with golimumab. <i>Rheumatology International</i> , 2018, 38, 161-167.	3.0	11
76	OP0092...Decreased dickkopf-1 expression in clinically uninvolved skin from patients with systemic sclerosis. , 2018, , .		0
77	Prevalence of comorbidities in systemic sclerosis versus rheumatoid arthritis: a comparative, multicenter, matched-cohort study. <i>Arthritis Research and Therapy</i> , 2018, 20, 267.	3.5	24
78	Prospects of using cardiovascular magnetic resonance in the identification of arrhythmogenic substrate in autoimmune rheumatic diseases. <i>Rheumatology International</i> , 2018, 38, 1615-1621.	3.0	10
79	The Role of Statins in Disease Modification and Cardiovascular Risk in Rheumatoid Arthritis. <i>Frontiers in Medicine</i> , 2018, 5, 24.	2.6	43
80	Novel insights into the role of inflammasomes in autoimmune and metabolic rheumatic diseases. <i>Rheumatology International</i> , 2018, 38, 1345-1354.	3.0	18
81	Multicenter Cross-sectional Study of Patients with Rheumatoid Arthritis in Greece: Results from a cohort of 2.491 patients. <i>Mediterranean Journal of Rheumatology</i> , 2018, 29, 27-37.	0.8	13
82	AB0421...Low rates of retention of biologic dmard monotherapy in patients with rheumatoid arthritis in real life settings. , 2018, , .		0
83	THU0102...High rates of residual disease activity despite current therapies in a real life rheumatoid arthritis cohort: data from 1096 patients. , 2018, , .		0
84	THU0427...Comparable cardiovascular disease and neoplasm rates but higher frequency of depression in systemic sclerosis versus rheumatoid arthritis: a multicentre comparative study of comorbidities. , 2018, , .		0
85	Mediterranean Journal of Rheumatology December 2018 Highlights. <i>Mediterranean Journal of Rheumatology</i> , 2018, 29, 182-183.	0.8	0
86	Combined brain and heart magnetic resonance imaging in systemic vasculitides: fiction or real need?. <i>Clinical and Experimental Rheumatology</i> , 2018, 36 Suppl 111, 152-159.	0.8	4
87	Dickkopf-1 is downregulated early and universally in the skin of patients with systemic sclerosis despite normal circulating levels. <i>Clinical and Experimental Rheumatology</i> , 2018, 36 Suppl 113, 45-49.	0.8	3
88	Cardiovascular magnetic resonance imaging pattern at the time of diagnosis of treatment naïve patients with connective tissue diseases. <i>International Journal of Cardiology</i> , 2017, 236, 151-156.	1.7	45
89	Endothelial injury in rheumatoid arthritis: a crosstalk between dimethylarginines and systemic inflammation. <i>Arthritis Research and Therapy</i> , 2017, 19, 32.	3.5	46
90	Genetic variations in the alanine-glyoxylate aminotransferase 2 (AGXT2) gene and dimethylarginines levels in rheumatoid arthritis. <i>Amino Acids</i> , 2017, 49, 1133-1141.	2.7	4

#	ARTICLE	IF	CITATIONS
91	The role of nailfold capillaroscopy in the assessment of internal organ involvement in systemic sclerosis: A critical review. <i>Autoimmunity Reviews</i> , 2017, 16, 787-795.	5.8	39
92	Biologic drugs as analgesics for the management of osteoarthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 46, 687-691.	3.4	19
93	Subjective and Objective Measures of Dryness Symptoms in Primary Sjögren's Syndrome: Capturing the Discrepancy. <i>Arthritis Care and Research</i> , 2017, 69, 1714-1723.	3.4	18
94	Predictors and long-term outcome in Greek adults with juvenile idiopathic arthritis: a 17-year continuous follow-up study. <i>Rheumatology</i> , 2017, 56, 1928-1938.	1.9	22
95	Cardiac Tissue Characterization and Imaging in Autoimmune Rheumatic Diseases. <i>JACC: Cardiovascular Imaging</i> , 2017, 10, 1387-1396.	5.3	26
96	Risk factors for cardiovascular disease in rheumatoid arthritis. , 2017, , 39-52.		0
97	Complementary role of cardiovascular imaging and laboratory indices in early detection of cardiovascular disease in systemic lupus erythematosus. <i>Lupus</i> , 2017, 26, 227-236.	1.6	26
98	A critical view on cardiovascular risk in systemic sclerosis. <i>Rheumatology International</i> , 2017, 37, 85-95.	3.0	38
99	FRI0173â€¦Correlation between asymmetric dimethylarginine and homocysteine levels in patients with rheumatoid arthritis. , 2017, , .		0
100	Autoimmune Thrombotic Thrombocytopenic Purpura: Two Rare Cases Associated with Juvenile Idiopathic Arthritis and Multiple Sclerosis. <i>Frontiers in Medicine</i> , 2017, 4, 89.	2.6	7
101	Cardiovascular risk in systemic sclerosis: Micro- and Macro-vascular involvement. <i>Indian Journal of Rheumatology</i> , 2017, 12, 211.	0.4	5
102	THU0113â€¦Genetic Variations in The Alanine-Glyoxylate Aminotransferase-2 (AGXT-2) Gene Are Not Related To Levels of Dimethylarginines in Patients with Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 220.2-220.	0.9	0
103	Cardiovascular magnetic resonance in rheumatology: Current status and recommendations for use. <i>International Journal of Cardiology</i> , 2016, 217, 135-148.	1.7	114
104	In vivomicrovascular and macrovascular endothelial function is not associated with circulating dimethylarginines in patients with rheumatoid arthritis: a prospective analysis of the DRACCO cohort. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2016, 76, 331-337.	1.2	12
105	Cardiovascular risk in rheumatoid arthritis: assessment, management and next steps. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2016, 8, 86-101.	2.7	56
106	Phenotyping Exercise Limitation in Systemic Sclerosis: The Use of Cardiopulmonary Exercise Testing. <i>Respiration</i> , 2016, 91, 115-123.	2.6	16
107	Associations between asymmetric dimethylarginine, homocysteine, and the methylenetetrahydrofolate reductase (<i>MTHFR</i>) C677T polymorphism (rs1801133) in rheumatoid arthritis. <i>Scandinavian Journal of Rheumatology</i> , 2016, 45, 267-273.	1.1	13
108	Imaging Patterns of Cardiovascular Involvement in Mixed Connective Tissue Disease Evaluated by Cardiovascular Magnetic Resonance. <i>Inflammation and Allergy: Drug Targets</i> , 2016, 14, 111-116.	1.8	11

#	ARTICLE	IF	CITATIONS
109	Symmetric Dimethylarginine Is Not Associated with Cumulative Inflammatory Load or Classical Cardiovascular Risk Factors in Rheumatoid Arthritis: A 6-Year Follow-Up Study. <i>Mediators of Inflammation</i> , 2015, 2015, 1-8.	3.0	4
110	Cumulative inflammation associates with asymmetric dimethylarginine in rheumatoid arthritis: a 6 year follow-up study. <i>Rheumatology</i> , 2015, 54, 1145-1152.	1.9	31
111	Symmetric dimethylarginine (SDMA) serum levels in rheumatoid arthritis: correlations with insulin resistance and disease activity scores. <i>Amino Acids</i> , 2015, 47, 1995-2004.	2.7	14
112	Deciphering Cardiovascular Disease in Systemic Inflammatory Diseases Using Advanced Magnetic Resonance Imaging. <i>Current Cardiovascular Imaging Reports</i> , 2015, 8, 1.	0.6	0
113	Infliximab as a treatment option for patients with rheumatoid arthritis and primary biliary cirrhosis. <i>Rheumatology International</i> , 2015, 35, 1913-1916.	3.0	11
114	FRIO100â€¦The Role of Insulin Resistance and Inflammation on Symmetric Dimethylarginine in Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 456.1-456.	0.9	0
115	Molecular and Cellular Pathways as Treatment Targets for Biologic Therapies in Systemic Sclerosis. <i>Current Medicinal Chemistry</i> , 2015, 22, 1943-1955.	2.4	15
116	109.â€¦UK Clinical Practice Use of Biologics in Monotherapy for the Treatment of Patients with Rheumatoid Arthritis. <i>Rheumatology</i> , 2014, 53, i99-i99.	1.9	0
117	Edema and fibrosis imaging by cardiovascular magnetic resonance: How can the experience of Cardiology be best utilized in rheumatological practice?. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 44, 76-85.	3.4	11
118	Osteoarthritis pain has a significant neuropathic component: an exploratory in vivo patient model. <i>Rheumatology International</i> , 2014, 34, 315-320.	3.0	20
119	Relationship between dimethylarginine dimethylaminohydrolase gene variants and asymmetric dimethylarginine in patients with rheumatoid arthritis. <i>Atherosclerosis</i> , 2014, 237, 38-44.	0.8	13
120	Individualised exercise improves endothelial function in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 748-751.	0.9	92
121	Asymmetric dimethylarginine is not associated with subendocardial viability ratio in Rheumatoid Arthritis. <i>International Journal of Cardiology</i> , 2014, 172, 285-286.	1.7	8
122	Neuropathic pain in osteoarthritis: A review of pathophysiological mechanisms and implications for treatment. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 44, 145-154.	3.4	157
123	Micro- and Macrovascular Treatment Targets in Scleroderma Heart Disease. <i>Current Pharmaceutical Design</i> , 2014, 20, 536-544.	1.9	35
124	Rheumatoid Arthritis: An Autoimmune Disease with Female Preponderance and Cardiovascular Risk Equivalent to Diabetes Mellitus: Role of Cardiovascular Magnetic Resonance. <i>Inflammation and Allergy: Drug Targets</i> , 2014, 13, 81-93.	1.8	20
125	Cardiac and Muscular Involvement in Idiopathic Inflammatory Myopathies: Noninvasive Diagnostic Assessment and the Role of Cardiovascular and Skeletal Magnetic Resonance Imaging. <i>Inflammation and Allergy: Drug Targets</i> , 2014, 13, 206-216.	1.8	28
126	Why currently used diagnostic techniques for heart failure in rheumatoid arthritis are not enough: the challenge of cardiovascular magnetic resonance imaging. <i>Reviews in Cardiovascular Medicine</i> , 2014, 15, 320-31.	1.4	6

#	ARTICLE	IF	CITATIONS
127	Why Currently Used Diagnostic Techniques for Heart Failure in Rheumatoid Arthritis Are Not Enough: The Challenge of Cardiovascular Magnetic Resonance Imaging. <i>Reviews in Cardiovascular Medicine</i> , 2014, 15, 320-331.	1.4	15
128	Lack of association between polymorphisms of thrombogenic genes and disease susceptibility in rheumatoid arthritis. <i>Rheumatology International</i> , 2013, 33, 2429-2432.	3.0	0
129	Derangement of hemostasis in rheumatoid arthritis: association with demographic, inflammatory and metabolic factors. <i>Clinical Rheumatology</i> , 2013, 32, 1357-1364.	2.2	17
130	Clinical outcome of ultrasound-guided steroid injections for chronic shoulder pain. <i>International Journal of Rheumatic Diseases</i> , 2013, 16, 398-402.	1.9	3
131	Heart involvement in rheumatoid arthritis: Multimodality imaging and the emerging role of cardiac magnetic resonance. <i>Seminars in Arthritis and Rheumatism</i> , 2013, 43, 314-324.	3.4	32
132	The Role of Multimodality Imaging in the Evaluation of Takayasu Arteritis. <i>Seminars in Arthritis and Rheumatism</i> , 2013, 42, 401-412.	3.4	73
133	Predictors of asymmetric dimethylarginine levels in patients with rheumatoid arthritis: the role of insulin resistance. <i>Scandinavian Journal of Rheumatology</i> , 2013, 42, 176-181.	1.1	19
134	Biologic therapies and systemic bone loss in rheumatoid arthritis. <i>Autoimmunity Reviews</i> , 2013, 12, 958-966.	5.8	72
135	Asymmetric Dimethylarginine as a Surrogate Marker of Endothelial Dysfunction and Cardiovascular Risk in Patients with Systemic Rheumatic Diseases. <i>International Journal of Molecular Sciences</i> , 2012, 13, 12315-12335.	4.1	37
136	B-type natriuretic peptide in rheumatic diseases: A cardiac biomarker or a sophisticated acute phase reactant?. <i>Autoimmunity Reviews</i> , 2012, 11, 837-843.	5.8	12
137	Multimodality imaging and the emerging role of cardiac magnetic resonance in autoimmune myocarditis. <i>Autoimmunity Reviews</i> , 2012, 12, 305-312.	5.8	34
138	Clinical remission following treatment with tumour necrosis factor-alpha antagonists is not accompanied by changes in asymmetric dimethylarginine in patients with rheumatoid arthritis. <i>Clinical Biochemistry</i> , 2012, 45, 1399-1403.	1.9	24
139	Imaging modalities for the diagnosis of pulmonary hypertension in systemic sclerosis. <i>Nature Reviews Rheumatology</i> , 2012, 8, 203-213.	8.0	27
140	Systemic Sclerosis-Related Pulmonary Hypertension: Unique Characteristics and Future Treatment Targets. <i>Current Pharmaceutical Design</i> , 2012, 18, 1457-1464.	1.9	13
141	Lack of association between asymmetric dimethylarginine and in vivo microvascular and macrovascular endothelial function in patients with rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2012, 30, 388-96.	0.8	27
142	Significance of serum uric acid in pulmonary hypertension due to systemic sclerosis: a pilot study. <i>Rheumatology International</i> , 2011, 31, 263-267.	3.0	37
143	Biomarkers in Systemic Sclerosis-Related Pulmonary Arterial Hypertension. <i>Current Vascular Pharmacology</i> , 2011, 9, 213-219.	1.7	7
144	Left atrial volume and N-terminal pro-B type natriuretic peptide are associated with elevated pulmonary artery pressure in patients with systemic sclerosis. <i>Clinical Rheumatology</i> , 2010, 29, 957-964.	2.2	35

#	ARTICLE	IF	CITATIONS
145	Natriuretic Peptides in Systemic Sclerosis-related Pulmonary Arterial Hypertension. <i>Seminars in Arthritis and Rheumatism</i> , 2010, 39, 278-284.	3.4	23
146	Effects of Renin-Angiotensin System Inhibition on Left Atrial Function of Hypertensive Patients: An Echocardiographic Tissue Deformation Imaging Study. <i>American Journal of Hypertension</i> , 2010, 23, 556-561.	2.0	27
147	Early Detection of Cardiac Involvement in Systemic Sclerosis Assessed by Tissue-Doppler Echocardiography: Relationship with Neurohormonal Activation and Endothelial Dysfunction. <i>Journal of Rheumatology</i> , 2010, 37, 993-999.	2.0	44
148	Scleroderma Renal Crisis Accompanied by New-Onset Pulmonary Hypertension: An Acute Systemic Endothelial Injury? Case Report and Literature Review. <i>Inflammation and Allergy: Drug Targets</i> , 2010, 9, 313-318.	1.8	6
149	N-terminal pro-brain natriuretic peptide in systemic sclerosis related pulmonary arterial hypertension under bosentan treatment. <i>Rheumatology International</i> , 2009, 29, 347-348.	3.0	4
150	Paget's disease of the vulva in a patient with scleroderma and underlying adenocarcinoma: case report. <i>European Journal of Gynaecological Oncology (discontinued)</i> , 2009, 30, 458-9.	0.2	2
151	N-Terminal probrain natriuretic peptide as a biochemical marker in the evaluation of bosentan treatment in systemic-sclerosis-related pulmonary arterial hypertension. <i>Clinical Rheumatology</i> , 2008, 27, 655-658.	2.2	20
152	Limitations of the findings regarding the relationship between N-terminal pro-brain natriuretic peptide and systemic sclerosis-related pulmonary arterial hypertension: Comment on the article by Allanore et al. <i>Arthritis and Rheumatism</i> , 2008, 58, 2215-2216.	6.7	3
153	Asymmetrical dimethylarginine in systemic sclerosis-related pulmonary arterial hypertension. <i>Rheumatology</i> , 2008, 47, 1682-1685.	1.9	44
154	Neurohormonal activation in patients with systemic sclerosis-related pulmonary arterial hypertension. <i>International Journal of Cardiology</i> , 2007, 121, 135-137.	1.7	20
155	N-Terminal Pro-Brain Natriuretic Peptide Levels Are Elevated in Patients with Acute Ischemic Stroke. <i>Angiology</i> , 2005, 56, 723-730.	1.8	55
156	How Should Concurrent Arterial and Venous Thrombosis Associated With SARS-CoV-2 Infection Be Managed. <i>European Journal of Case Reports in Internal Medicine</i> , 0, , .	0.4	0